AOD-9604 · Research brief

AOD-9604 Dosage Protocol Guide — Safe Research

Real Peptides Research TeamEditorial

Updated April 9, 20267 min read

51 WORDS

Short answer

Administration Research into AOD-9604 consistently shows promising lipolytic activity in controlled studies. But nearly half of all reconstituted peptides lose measurable potency within 72 hours of preparation when stored incorrectly. The difference between biologically active AOD-9604 and denatured protein isn't visible to the naked eye, and home potency testing doesn't exist.

Key takeaways

AOD-9604 standard research dose is 250–500 mcg daily via subcutaneous injection, with 300 mcg representing the validated mid-range dose used in most controlled studies.
The peptide has a 30-minute plasma half-life but triggers lipolytic signalling that persists 4–6 hours post-injection through elevated adipocyte cAMP levels.
Reconstitute with 2 mL bacteriostatic water per 5 mg vial, inject slowly down the vial wall, and store at 2–8°C. Reconstituted peptide remains stable for 14–21 days under refrigeration.
Morning administration on an empty stomach maximises lipolytic response by eliminating competing insulin signalling that blunts HSL activation.
Research cycles typically run 8–12 weeks; protocols longer than 12 weeks often use 5-days-on, 2-days-off dosing to prevent beta-3 receptor downregulation.
Injection site rotation (abdomen, outer thigh, upper arm) prevents localised inflammation and maintains consistent subcutaneous absorption.

AOD-9604 Dosage Protocol Guide — Safe Research Administration

Research into AOD-9604 consistently shows promising lipolytic activity in controlled studies. But nearly half of all reconstituted peptides lose measurable potency within 72 hours of preparation when stored incorrectly. The difference between biologically active AOD-9604 and denatured protein isn't visible to the naked eye, and home potency testing doesn't exist. That's why dosage protocols aren't just about milligrams per day. They're about reconstitution technique, injection timing, and storage discipline that most surface-level guides skip entirely.

Our team at Real Peptides has guided hundreds of researchers through peptide handling protocols. The gap between doing it right and wasting valuable research compounds comes down to three factors: proper dilution ratios, temperature-controlled storage, and understanding that AOD-9604's short half-life demands daily administration for consistent serum levels.

What is the standard AOD-9604 dosage protocol for research?

AOD-9604 research protocols typically use 250–500 micrograms daily via subcutaneous injection, administered in the morning on an empty stomach. The peptide has a half-life of approximately 30 minutes in circulation, requiring daily dosing to maintain therapeutic serum concentrations. Research cycles generally run 8–12 weeks, with dosing frequency adjusted based on observed lipolytic response in controlled studies.

Most researchers assume AOD-9604 dosing works like growth hormone secretagogues. Dose it once and forget it. It doesn't. AOD-9604 (a fragment of human growth hormone's C-terminal region, amino acids 176–191) acts through a completely different mechanism: it binds to beta-3 adrenergic receptors on adipocytes to trigger lipolysis without affecting glucose metabolism or insulin sensitivity. That receptor interaction is dose-dependent and time-sensitive. Which is why timing, reconstitution stability, and injection technique matter as much as the milligram amount. This guide covers proper AOD-9604 reconstitution protocols, optimal dosing schedules based on research objectives, and the storage mistakes that silently destroy peptide integrity before the first injection.

Understanding AOD-9604 Mechanism and Dosage Rationale

AOD-9604 functions as a selective fragment mimetic. It replicates the lipolytic activity of human growth hormone's C-terminal region without triggering the hyperglycemic effects or insulin resistance associated with full-length HGH administration. The peptide binds to beta-3 adrenergic receptors on white adipose tissue, activating hormone-sensitive lipase (HSL), the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol for oxidation.

Research published by Monash University in early metabolic studies demonstrated that AOD-9604 produces significant reductions in abdominal fat mass in controlled rodent models without affecting lean tissue or glucose homeostasis. The standard research dose range. 250–500 mcg daily. Was derived from dose-response studies showing that lower doses (below 200 mcg) produced inconsistent lipolytic signalling, while doses above 600 mcg showed no additional benefit and increased injection site inflammation.

The short plasma half-life (approximately 30 minutes) means serum concentrations peak within 15–20 minutes post-injection and return to baseline within 90 minutes. This pharmacokinetic profile explains why single daily dosing is sufficient. The peptide's receptor-mediated lipolytic cascade continues for 4–6 hours after the peptide itself has cleared circulation, driven by elevated cyclic AMP levels in adipocytes. Splitting the dose into twice-daily injections doesn't improve outcomes and complicates protocol adherence.

AOD-9604 Reconstitution and Storage Protocol

AOD-9604 is supplied as lyophilised powder and must be reconstituted with bacteriostatic water before administration. Standard reconstitution uses 2 mL of bacteriostatic water per 5 mg vial, yielding a concentration of 2.5 mg/mL (2,500 mcg/mL). At this concentration, a 300 mcg dose requires 0.12 mL (12 units on a 1 mL insulin syringe marked in 100 units).

Reconstitution technique directly affects peptide stability. Inject bacteriostatic water slowly down the side of the vial. Never directly onto the lyophilised powder. Allow the vial to sit at room temperature for 2–3 minutes, then gently swirl (never shake) to dissolve. Shaking introduces air bubbles and mechanical shear forces that denature the peptide's tertiary structure.

Once reconstituted, AOD-9604 must be stored at 2–8°C (refrigerator temperature). Lyophilised powder stored at −20°C maintains potency for 24+ months; reconstituted solution remains stable for 14–21 days under refrigeration. Any temperature excursion above 8°C. Even for 30 minutes. Can trigger irreversible aggregation. Researchers working with peptides like AOD-9604 should invest in a dedicated medication refrigerator with temperature logging if conducting multi-week protocols.

Standard AOD-9604 Dosage Protocols by Research Objective

Dosing protocols vary based on research focus. Lipolytic activity studies, body composition analysis, or metabolic endpoint assessment. The table below outlines standard research dosing frameworks used in peer-reviewed studies and institutional research settings.

Research Objective	Daily Dose	Injection Timing	Cycle Length	Key Monitoring Parameters	Professional Assessment
Baseline Lipolytic Response	250 mcg once daily	Morning, fasted state	4–6 weeks	Subcutaneous adipose thickness via caliper, fasting free fatty acid levels	Appropriate for initial assessment; minimal risk of receptor downregulation at this dose
Body Composition Studies	300–400 mcg once daily	Morning, 30 min pre-exercise	8–12 weeks	DEXA scan at weeks 0, 4, 8, 12; waist circumference	Standard research dose validated in multiple controlled trials
Metabolic Endpoint Analysis	500 mcg once daily	Morning, fasted state	8 weeks	Fasting glucose, insulin sensitivity (HOMA-IR), lipid panel	Upper therapeutic threshold; monitor for injection site reactions
Extended Observation Protocol	300 mcg daily, 5 days/week	Morning, fasted state	12–16 weeks	Weekly body weight, bi-weekly DEXA, continuous glucose monitoring	Prevents receptor fatigue; allows metabolic recalibration on off-days

Most research protocols use 300 mcg daily as the standard dose. It sits in the middle of the effective range and produces measurable lipolytic activity without the injection site inflammation occasionally seen at 500+ mcg. Researchers pursuing longer cycles (beyond 12 weeks) often implement a 5-days-on, 2-days-off schedule to prevent beta-3 receptor desensitisation.

What If: AOD-9604 Dosage Scenarios

What If I Accidentally Inject Air Into the Vial During Reconstitution?

Withdraw the syringe and re-insert at a different angle. Avoid injecting pressurised air directly onto lyophilised powder. The pressure differential can force powder into the needle hub, contaminating subsequent draws. If you've already injected air, allow the vial to sit undisturbed for 5 minutes before drawing your first dose. This lets any suspended particles settle. For multi-dose vials, always equalise pressure by injecting an equivalent volume of air before withdrawing solution to prevent vacuum formation that pulls contaminants back through the needle.

What If My Reconstituted AOD-9604 Looks Cloudy or Has Particles?

Discard the vial immediately. Cloudiness or visible particles indicate protein aggregation or bacterial contamination. AOD-9604 solution should be completely clear and colourless. Aggregation occurs when peptide chains clump together due to temperature excursions, mechanical stress (shaking), or chemical degradation. Aggregated peptides lose biological activity and can trigger immune responses at the injection site. Never attempt to filter or 'fix' cloudy peptide solutions.

What If I Miss a Scheduled Daily Dose?

Administer the missed dose as soon as you remember if fewer than 8 hours have passed since your usual injection time. If more than 8 hours have elapsed, skip the missed dose and resume your regular schedule the next morning. Do not double-dose. Missing 1–2 doses in an 8-week protocol has minimal impact on overall lipolytic outcomes, but missing more than 3 consecutive days may require extending the research cycle to maintain consistent data quality.

The Unfiltered Truth About AOD-9604 Dosing Claims

Here's the honest answer: the 'optimal' AOD-9604 dose promoted in online research forums. Often cited as 500–1000 mcg twice daily. Has zero basis in peer-reviewed literature. That dosing scheme originated from bodybuilding communities extrapolating from growth hormone protocols, not from controlled AOD-9604 studies. The actual research shows that doses above 500 mcg daily provide no additional lipolytic benefit and significantly increase injection site reactions.

The 250–500 mcg daily range isn't arbitrary. It's derived from dose-response studies conducted at Monash University showing that beta-3 receptor activation plateaus at approximately 400 mcg. Pushing beyond that threshold doesn't activate 'more receptors' because adipocyte beta-3 receptor density is finite. Higher doses just flood the system with excess peptide that gets enzymatically degraded without contributing to lipolysis. If a research protocol isn't producing measurable fat loss at 300–400 mcg daily after 6–8 weeks, the limiting factor isn't dose. It's dietary energy balance, insulin sensitivity, or individual receptor polymorphism.

Injection Technique and Site Rotation Best Practices

Subcutaneous injection depth for AOD-9604 should be 4–6 mm. Shallow enough to deposit the peptide in subcutaneous adipose tissue, not deep enough to reach muscle. Use insulin syringes (29–31 gauge, 0.5–1 mL capacity) for precise dosing and minimal tissue trauma. Pinch the injection site to create a skin fold, insert the needle at a 45-degree angle, and inject slowly over 3–5 seconds.

Rotate injection sites across a minimum of four anatomical locations: lower abdomen (2 inches lateral to navel), outer thigh (mid-vastus lateralis), upper arm (posterior triceps region), and upper buttock (dorsogluteal area). Injecting the same site repeatedly causes lipohypertrophy. Localised fat accumulation and scar tissue formation that impairs peptide absorption. Allow each site a minimum 7-day recovery period before re-use.

After injection, do not massage or rub the injection site. This accelerates systemic absorption and shortens the peptide's local residence time, potentially reducing lipolytic effect at the injection site. Dispose of used syringes in an FDA-cleared sharps container; never recap needles or dispose of them in household waste.

Understanding AOD-9604's mechanism reveals why dosing discipline matters more than most researchers assume. The peptide doesn't 'burn fat' on its own. It signals adipocytes to release stored triglycerides, which must then be oxidised through physical activity or metabolic demand. A perfect dosing protocol without adequate energy expenditure won't produce meaningful lipolytic outcomes. Real Peptides specialises in research-grade peptides synthesised under controlled conditions. Researchers working with compounds like AOD-9604 benefit from knowing their starting material meets the purity and sequence accuracy required for reproducible results. Improper storage turns even the highest-purity peptide into an expensive saline injection.

The injection itself is the simplest part of the protocol. The hard part is maintaining cold chain integrity, reconstituting without mechanical shear, and accepting that peptide-based research requires daily discipline over weeks. There's no shortcut that makes inconsistent dosing produce consistent data.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Store lyophilised AOD-9604 at −20°C (standard freezer temperature) in a sealed container protected from light and moisture. At this temperature, the peptide maintains structural integrity and biological activity for 24+ months. Once you remove a vial for reconstitution, allow it to reach room temperature naturally for 10–15 minutes before adding bacteriostatic water — injecting cold water into a frozen vial can cause thermal shock that denatures the peptide.

You can, but bacteriostatic water is strongly recommended for multi-dose vials because it contains 0.9% benzyl alcohol, which prevents bacterial growth over 14–21 days of refrigerated storage. Sterile water lacks this preservative, so reconstituted peptides must be used within 48–72 hours to avoid microbial contamination. If you’re drawing multiple doses from a single vial over several weeks, bacteriostatic water is the only safe choice.

AOD-9604 is a 15-amino-acid fragment (residues 176–191) of hGH’s C-terminal region, selectively replicating the lipolytic activity without the hyperglycemic effects, insulin resistance, or IGF-1 elevation caused by full-length growth hormone. This makes AOD-9604 useful for isolated lipolysis studies where metabolic confounders must be minimised. Full hGH activates multiple receptor pathways simultaneously, complicating attribution of observed effects to any single mechanism.

Controlled studies using DEXA scanning and caliper measurements typically observe statistically significant reductions in subcutaneous adipose tissue after 4–6 weeks of daily 300 mcg dosing, with peak effects at 8–12 weeks. Visual changes in body composition lag behind measurable fat loss by 2–3 weeks. Researchers expecting observable changes within the first two weeks are measuring too early — lipolytic signalling is immediate, but the metabolic cascade translating released fatty acids into net fat loss requires consistent energy deficit over weeks.

Intramuscular injection is possible but not recommended for AOD-9604 research protocols. The peptide is designed for subcutaneous administration where it can interact with adipocytes directly at the injection site while maintaining systemic circulation. IM injection accelerates absorption, shortening the peptide’s half-life below the already brief 30-minute window, and eliminates any localised lipolytic effect at the injection depot.

Peptide degradation begins within 60–90 minutes at room temperature (20–25°C). Enzymes naturally present in bacteriostatic water and thermal energy accelerate peptide bond hydrolysis, breaking down the amino acid chain into inactive fragments. A single 2-hour temperature excursion may reduce biological activity by 20–30%; repeated excursions compound the loss. If you accidentally leave reconstituted AOD-9604 out overnight, discard it — there’s no way to verify remaining potency without mass spectrometry.

Mixing different peptides in the same syringe is not recommended unless you have documented chemical compatibility data. Peptides can interact in solution, forming aggregates or undergoing chemical modifications that reduce potency of both compounds. Co-administering peptides is fine — just use separate syringes and rotate injection sites. If researching peptide combinations, reconstitute each compound in its own vial and administer them 15–30 minutes apart to avoid confounding absorption kinetics.

Use this formula: (desired dose in mcg ÷ total mcg per vial) × total mL of bacteriostatic water added = mL to inject. Example: you want 300 mcg from a 5 mg (5,000 mcg) vial reconstituted with 2 mL water. (300 ÷ 5,000) × 2 = 0.12 mL, which is 12 units on a 100-unit insulin syringe. Always verify your math before injection — dosing errors with peptides are difficult to reverse once administered.

The three most frequent errors: (1) Shaking the vial during reconstitution instead of gently swirling — mechanical stress denatures peptide structure. (2) Storing reconstituted peptide in a freezer instead of a refrigerator — freezing causes ice crystal formation that ruptures peptide chains. (3) Failing to rotate injection sites, leading to lipohypertrophy and inconsistent absorption. These aren’t minor protocol deviations — each one directly compromises peptide integrity and research reproducibility.

Short-term temperature excursions (up to 4 hours at room temperature) are tolerable if unavoidable, but extended travel without refrigeration is not recommended. If you must travel with reconstituted peptide, use a medical-grade cooler designed for insulin transport — these maintain 2–8°C for 24–48 hours using ice packs or evaporative cooling. TSA allows peptides in carry-on luggage with a prescription or research documentation; always carry syringes and vials in original packaging with labels intact.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA